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This pilot-study evaluated the toxicity and safety profi le of  two herbal products Souroubea 
spp Botanical Blend (SSBB) and Platanus Tree Bark (PTB) after oral administration to 
dogs at elevated doses for 28 days. SSBB and PTB botanicals are the major active 
ingredients of  Sin Susto™, a novel natural product for the treatment of  anxiety in 
dogs. Three healthy female dogs were administered elevated doses of  either SSBB, PTB 
or a placebo and then monitored for the occurrence of  any systemic and local adverse 
events. Data from this pilot-study revealed that SSBB and PTB had no untoward effects 
on the health of  dogs and were deemed safe which enabled the design and execution of  
a larger controlled target safety and toxicology study for Sin Susto™.
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INTRODUCTION
Anxiety and aversion to loud sounds (noise aversion) are common behavioural problems 
in companion anim als, particularly dogs. These behaviours are associated with fear 
responses, such as cowering, freezing, scanning, seeking out the owner, and attempting 
to escape. In some cases, anxiety may lead to property damage, dog injury, disruption 
of  the owner-pet bond and potential pet abandonment or even euthanasia [1,2]. If  left 
untreated anxiety may have a negative impact on overall animal health and reduce their 
lifespan [3]. Current treatments for anxiety and noise aversion in veterinary medicine 
include pharmacotherapy (benzodiazepines, phenothiazines, tricyclic antidepressants 
(TCAs) selective serotonin reuptake inhibitors (SSRI) behavioural management, 
systematic desensitization [1] and use of  neutraceuticals [4].
Sin Susto™ (Bioniche Animal Health., Belleville, ON, Canada) is a herbal natural 
anxiolytic product intended to prevent or reduce both anxiety and stress in dogs. Sin 
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Susto™ is formulated as a chewable tablet containing a blend of  natural botanical 
ingredients: Souroubea spp. Botanical Blend (SSBB) and Platanus spp. Tree Bark (PTB). 
SSBB is known and accurately defi ned as “leaf  and stem growth” of  the neotropical 
vines: Souroubea sympetela Gilg. or Souroubea gilgii V.A. Richt. (Marcgraviaceae) or any 
mixture of  both. PTB is defi ned as the shed bark of  Platanus occidentalis L. (American 
Sycamore) or Platanus acerfolia Aiton Wild. (London Planetree) (Plantanaceae) or any 
mixture of  these. 
MATERIALS AND METHODS
Preparation and characterization of SSBB and PTB
The biochemical screening of  the genus Souroubea spp. and Platanus spp. by the Biology 
and Chemistry Department at the University of  Ottawa has not demonstrated any 
signifi cant differences in the levels of  the pentacyclic triterpenoids between the two 
species in each genus. The leaves and stems of  Souroubea sympetala (UNA voucher 
no. JVR 12823) and Souroubea gilgii (UNA voucher no. JVR 12844 and JVR 12894) 
samples used in this pilot study were collected in Costa Rica. The Platanus occidentalis 
and Pacerifolia (OTT voucher no. 19608/9) samples were collected in Ottawa, Ontario, 
Canada. SSBB and PTB were prepared by drying in a herb drier at 45°C, thereon 
grinding the dried herbal material to a fi ne powder that passes through a 0.25 mm 
screen and thoroughly blending together. In both, SSBB and PTB the betulinic acid 
(BA) is considered to be the major active component. Both species were analysed 
for BA content by HPLC/MS methods as previously described  [5]. BA possesses 
anxiolytic properties at low doses (1 mg/kg) [6] and has  potential benefi ts  in canc er 
therapy [7,8] reduction of  HIV replication [9,10], infl ammation [11] and bacterial 
infections at much  higher doses (50-500 mg/kg) [12].
The primary objective of  this pilot study was to assess the safety of  each active herbal 
ingredient (AHI) SSBB and PTB at elevated doses after daily administration for 28 
days in dogs.
Each one of  the test articles (placebo, SSBB and PTB) were mixed with the double 
distilled water, commercial pet food (Eukanuba, Mfg230812 lot # 11134175), 
fl our and fl avour additive (Flavour Pal-beef  fl avour #U10K140) at the same ratio 
and provided in the form of  a dog treat (dog biscuit). Test articles were tested for 
triterpene levels (including BA) at the University of  Ottawa using high-performance 
liquid chromatography with tandem mass spectrometric   detection for the quantitative 
determination (HPLC-MS-QTRAP). Briefl y, biscuit samples were crushed in a blender 
and 2 g of  crushed material was used for extraction A with 250 ml ethyl acetate using 
a Soxhlet apparatus for 2h. The extracts were dried by rotatory evaporation at 45°C, 
re-dissolved in ethyl acetate and dried at room temperature. Extracts were solubilized 
in 40 ml methanol by sonication for 10 minutes and fi ltered through 0.22 micron 
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PTFE fi lter. One microliter was injected through an autosampler for HPLC-MS-MS 
analysis. Triterpene contents were quantifi ed by AB-SCIEX 3200 HPLC-MS-QTRAP. 
Method conditions: Column=Kinetex 2.6 micron, 100x2.00 mm Phenomenex; 
Mobile Phase=A-Water, B- Acetonitrile; Flow rate 0.4 mL/min; Column thermostat 
temperature +45°C; Separation: Linear Gradient+30-100% B in 18 min; Calibration 
curve was generated by injection of  1-200ug/ml purifi ed compounds from Sigma-
Aldrich or prepared by preparative HPLC. Analysis revealed that SSBB and PTB 
samples contained 0.22 (±0.034) mg/g and 0.68 (±0.016) mg/g of  BA, respectively. 
The test articles were supplied in identical labelled packages by Bioniche Animal 
Health and identifi ed as  Placebo, SSBB and PTB with respective lot numbers. The 
appearance and characteristics of  the products were visually similar. Upon receipt at 
the study site all test articles were stored in a freezer at -20°C to prevent deterioration. 
The study investigator was not blinded for experimental products. The technicians 
feeding and managing the dogs as well as laboratory personnel performing analysis 
were blinded for experimental treatments. 
Study design
The study protocol was developed by 3 study participants (Villalobos, Baker and 
Arnason) reviewed and approved by the University of  Ottawa Animal Care Committee 
(protocol #BL-146) and by the Ministry of  Science and Technology-National 
Technical Committee on the Use of  Laboratory Animals (PRONASEA), Costa Rica. 
The study was designed to avoid or minimize any discomfort, distress or pain to the 
animals during the course of  the experiment. The experimental design included an 
acclimatization period of  16 days (Days-16 to -1), test/dosing period of  28 days (Days 
0-28) and post-dosing monitoring period of  14 days (Days 29-42) (Table 1).
Three mixed-breed female dogs from a local shelter (Human Society, San Jose, Costa 
Rica) were randomly selected and enrolled in the study. Dogs enrolled in the study 
fulfi lled inclusion criteria (normal hematological, biochemical and urine analysis, 
approximately 2.5 years old, body condition score 1-3 [13], and without any clinical 
signs of  disease. The study site was the Veterinary Clinic Bethel Medical, San Jose, 
Costa Rica. Prior to the start of  the study the dogs were acclimatized for 16 days 
during which time they underwent clinical examination (Days-16, -6 and -1), blood 
and urine workup (Day-1). In addition, dogs were treated for internal (gastrointestinal) 
and external parasites (fl eas and ticks) at the beginning of  the acclimatization period 
(Day-16). During the acclimatization dogs were fed with placebo biscuits twice daily (3 
biscuits in the morning and 3 biscuits in the evening- approximately 10h apart).
Administrations of  test articles SSBB, PTB and placebo started on Day 0 and were 
performed twice daily for 28 consecutive days with the total daily dose split into 
half  and administered orally approximately 10h apart. The minimal effective dose is 
estimated to contain 1mg of  BA/kg of  body weight; therefore biscuits from both 
SSBB and PTB were formulated to contain 2 mg/g of  BA.
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RESULTS AND DISCUSSION
Dog #1 (7.2 kg) received three SSBB treats in the morning and three SSBB treats in 
the evening. Each SSBB treat contained 4.2g SSBB (8.4mg BA) which corresponded 
to seven times the recommended treatment dose of  SSBB (7 mg BA/kg/day). Dog 
#2 (9.8kg) also received three placebo treats in the morning and three placebo treats 
in the evening, which contained no SSBB or PTB (0 mg BA/kg/day). Lastly, Dog #3 
(17.5kg) received four PTB treats in the morning and three PTB treats in the evening, 
which was eight times higher than the daily recommended dose of  PTB (8 mg BA /
kg/day). Each PTB treat contained 1g PTB with 20 mg of  BA. 
Blood and urine samples were collected on days 0, 1, 3, 7, 14, 28, 35 and 42. Sampling 
was performed in the morning on each collection day. Dogs were fasted for 14 
to 16 hours prior to sample collection. In addition, on the sampling day the dogs 
were weighed and subjected to physical examination (temperature, pulse, heart rate, 
respiratory rate and capillary refi ll time). 
Dogs did not receive any concurrent medications during the course of  study (Days 0 
to 42). 
The blood samples were analyzed for the following parameters: urea, creatinine, red 
blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular 
hemoglobin, mean corpuscular hemoglobin concentration, white blood cell count, 
Table 1. Pilot-toxicology study schedule of  events for dogs receiving SSBB, 







































































1 ● ● ● ● ●
3 ● ● ● ● ●
7 ● ● ● ● ●
14 ● ● ● ● ●
28 ● ● ● ● ●
Post-treatment Period
(Day 29 to 42)




42 ● ● ● ● ●
aBlood samples obtained between 8:30 am and 9:30 am; bUrine samples obtained between 
6:00 am and 7:00 am; cTreatment administered at 9:30 am and 6:00 pm
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segmented neutrophil count, lymphocyte count, eosinophil count, monocyte count, 
platelets, calcium, phosphorus, magnesium, glucose, aspartate transaminase, glutamic 
pyruvic transaminase, alkaline phosphatase, gamma-glutamyl transpeptidase, total 
protein, albumin, globulin, A:G ratio, bilirubin, total cholesterol, chloride, sodium, 
potassium, total T3, free T4, cortisol, ACTH, TSH, and neutrophil:lymphocyte ratio. 
The urine samples were analyzed for the following: colour, turbidity, specifi c gravity, 
pH, albumin, glucose, ketones, nitrites, ascorbic acid, bilirubin, urobilinogen, blood, 
leukocytes, red blood cells, epithelial cells, mucus fi lament, crystals, amorphous 
sediment, and bacteria. During the course of  study dogs did not participate in any 
other experimental trials.
Throughout the study, the dogs were kept in clean cages, were exercised and monitored 
daily for any systemic or local changes. They were fed a diet of  Purina® Pro Plan® 
and had unrestricted access to fresh water. 
During the test/feeding stage of  the study (Days 0 to 28) and 14 days follow-up (Days 
29-42), all three dogs exhibited normal behaviour and there was no clinical evidence 
of  any local or systemic adverse reactions. Hematology, biochemistry and urinalyses 
results from all three dogs receiving either placebo, SSBB or PTB treats were within 
normal ranges. 
Slightly lower platelet counts in Dog 1 (SSBB) and Dog 2 (placebo) were considered 
to be related to a concurrent infection with Ehrlichia canis [14] which is endemic in 
Costa Rica [15]. In addition dog #1 developed slightly elevated globulin 3 days after 
the start of  treatment which was also attributed to concurrent Ehrlichia canis infection. 
Prior to their admission at the shelter, the dogs were strays and therefore were likely 
exposed to infection with Ehrlichia canis, which may explain the elevated globulin and 
thrombocytopenia observed in these two dogs. Incubation time following infection 
with Ehrlichia canis can be few weeks and during that time animals may not show any 
signs of  the disease. Despite mild thrombocytopenia and slightly elevated globulin the 
dogs did not show any clinical signs of  illness, nor did they show signs of  prolonged 
bleeding during sampling (Table 2). 
AHI, SSBB and PTB were orally administered to dogs at doses seven and eight times 
higher daily dose than the recommended daily dose; neither dose induced any systemic 








SSBB (7x) 1 28 days Transient thrombocytopenia from Day 3 to Day 14, no clinical signs of  illness.
PTB (8x) 1 28 days None
Placebo 1 28 days Transient thrombocytopenia from Day 3 to Day 14, elevated globulin, no clinical signs of  illness.
*SSBB = Souroubea spp Botanical Blend; PTB = Platanus Tree Bark
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or local adverse reactions which would be a safety concern for the dogs. Following the 
study the dogs were placed with new owners who have not reported any problems.
In conclusion, under the conditions of  this study and according to the data from 
daily observations, physical examinations, body weight, hematology, biochemical and 
urinalysis both SSBB and PTB had no untoward effects on the health of  dogs and 
were deemed safe.
The toxicology study with three dogs in Costa Rica served as a pilot screening for 
any negative health effects for each SSBB and PTB after prolonged and elevated 
administration. This study preceded the larger controlled target animal safety and 
toxicology trial (manuscript in preparation). Following the target safety study, an 
effi cacy study with age variable populations of  dogs was performed to evaluate Sin 
Susto™ as an anxiolytic product (manuscript in preparation). Furthermore, studies 
to evaluate the interaction of  Sin Susto™ with commonly prescribed drugs and the 
withdrawal effects after chronic use of  Sin Susto™ in dogs are underway.
Acknowledgement
The animal study was carried out in San Jose, Costa Rica using facilities provided 
by the Veterinary Clinic Bethel Medical. Funding for the pilot toxicology study was 
provided by the I2I grant program of  the Natural Sciences and Engineering Research 
Council of  Canada (NSERC).
We thank Paul Dick and Associates for advice on the study. 
REFERENCES
1. S herman BL, Mills DS: Canine anxieties and phobias: an update on separation anxiety 
and noise aversions. The Veterinary clinics of  North America Small animal practice 2008, 
38(5):1081-1106, vii.
2. S hull-Selcer EA, Stagg W: Advances in the understanding and treatment of  noise phobias. 
The Veterinary clinics of  North America Small animal practice 1991, 21(2):353-367.
3. D reschel NA: The effects of  fear and anxiety on health and lifespan in pet dogs. Applied 
Animal Behaviour Science 2010, 125:157-162.
4. J oseph A. Araujoa b, Christina de Riveraa,b, Jennifer L. Ethierb, Gary M. Landsbergb,c,, 
Sagi Denenbergc SA, Norton W. Milgrama,  : Anxitane tablets reduce fear of  human beings 
in a model of  anxiety-related behavior. Journal of  Veterinary Behavior 2010, 5:268-275.
5. M ullally M, Kramp K, Cayer C, Saleem A, Ahmed F, McRae C, Baker J, Goulah A, Otorola 
M, Sanchez P et al: Anxiolytic activity of  a supercritical carbon dioxide extract of  Souroubea 
sympetala (Marcgraviaceae). Phytotherapy research : PTR 2011, 25(2):264-270.
6. C ayer C: In vivo behavioural characterization of  anxiolytic botanicals: Souroubea sympetala. 
University of  Ottawa, Ottawa: University of  Ottawa, Ottawa; 2011.
7. P isha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, Beecher CW, Fong 
HH, Kinghorn AD, Brown DM et al: Discovery of  betulinic acid as a selective inhibitor 
Villalobos et al.
275
of  human melanoma that functions by induction of  apoptosis. Nature medicine 1995, 
1(10):1046-1051.
8. S imone Fulda M, Klaus-Michael Debatin: Betulinic acid induces apoptosis through a direct 
effect on mitochondria in meuroectodermal tumors. Medical and Pediatric Oncology 2000, 
35:616-618.
9. F ujioka T, Kashiwada Y, Kilkuskie RE, Cosentino LM, Ballas LM, Jiang JB, Janzen WP, 
Chen IS, Lee KH: Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV 
principles from Syzigium clavifl orum, and the anti-HIV activity of  structurally related 
triterpenoids. Journal of  natural products 1994, 57(2):243-247.
10. Kashiwada Y, Hashimoto F, Cosentino LM, Chen CH, Garrett PE, Lee KH: Betulinic 
acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. Journal of  medicinal 
chemistry 1996, 39(5):1016-1017.
11. Mukherjee PK, Saha K, Das J, Pal M, Saha BP: Studies on the anti-infl ammatory activity of  
rhizomes of  Nelumbo nucifera. Planta medica 1997, 63(4):367-369.
12.  Chandramu C, Manohar RD, Krupadanam DG, Dashavantha RV: Isolation, characterization 
and biological activity of  betulinic acid and ursolic acid from Vitex negundo L. Phytotherapy 
research : PTR 2003, 17(2):129-134.
13. DP. L: Development and Validation of  a Body Condition Score System for Dogs. Canine 
Practice 1997, 22:10-15.
14. Smith RD, Ristic M, Huxsoll DL, Baylor RA: Platelet kinetics in canine ehrlichiosis: 
evidence for increased platelet destruction as the cause of  thrombocytopenia. Infection 
and immunity 1975, 11(6):1216-1221.
15. Romero LE, Meneses AI, Salazar L, Jimenez M, Romero JJ, Aguiar DM, Labruna MB, Dolz 
G: First isolation and molecular characterization of  Ehrlichia canis in Costa Rica, Central 
America. Research in veterinary science 2011, 91(1):95-97.
KLINIČKA ZAPAŽANJA I BEZBEDNOST DVA BILJNA 
PROIZVODA SOUROUBEA I PLATANUS SPP NAKON ORALNE 
PRIMENE; PRELIMINARNA TOKSIKOLOŠKA ISPITIVANJA 
KOD PASA
VILLALOBOS Pedro, BAKER John, SANCHEZ VINDAS Pablo, DURST Tony, 
MASIC Aleksandar, ARNASON T John
Ova preliminarna studija procenjuje toksičnost i bezbednost dva biljna sastojka 
Souroubea spp Botanical Blend (SSBB) i Platanus Tree Bark (PTB) nakon oralne primene 
kod pasa u povišenim dozama u trajanju od 28 dana. Biljne mešavine SSBB i PTB su 
dva glavna aktivna sastojka u Sin Susto™, novog prirodnog proizvoda registrovanog 
za preventivu/smanjenje anksioznosti kod pasa. Tri zdrave ženke pasa su primale 
povišene doze SSBB, PTB ili placebo nakon čega je praćena pojava sistemskih ili 
lokalnih neželjenih efekata. Podaci iz ovog preliminarnog istraživanja su pokazali 
da SSBB i PTB nisu izazvali nikakve neželjene efekte kod pasa i mogu se smatrati 
bezbednim što je omogućilo dalje istraživanje i izvođenje kontrolisanih ispitivanja u 
cilju demonstriranja bezbednosti i toksičnosti preparata Sin Susto™ kod pasa.
